{
    "Symbol": "ALIVUS",
    "ISIN": "INE03Q201024",
    "News": [
        {
            "Title": "Alivus Life Sciences Reports Record Q3 FY26 Results",
            "Summary": "Alivus Life Sciences achieved highest-ever quarterly revenue of Rs. 673 crores with 14.4% QoQ growth and record EBITDA margins of 36.4% in Q3 FY26, driven by strong CDMO recovery and new product launches.",
            "Sentiment": "positive",
            "PublishDate": 1769799940861,
            "Source": "co_actions_results"
        },
        {
            "Title": "Alivus Life Sciences Eyes CDMO Growth by FY27",
            "Summary": "Alivus Life Sciences management anticipates concluding 1-2 additional CDMO projects by Q1 FY27 and expects double-digit growth from FY28-29, signaling strong expansion plans in contract development.",
            "Sentiment": "positive",
            "PublishDate": 1769138730367,
            "Source": "stocks"
        },
        {
            "Title": "Alivus Life Sciences Solapur Plant to Start by July",
            "Summary": "Alivus Life Sciences announces Solapur manufacturing plant expected to commence operations by July with projected capacity utilization of 85-90% once new capacity comes online.",
            "Sentiment": "positive",
            "PublishDate": 1769138697981,
            "Source": "stocks"
        },
        {
            "Title": "Alivus Life Sciences Revises FY26 CapEx Down",
            "Summary": "Alivus Life Sciences has revised its FY26 capital expenditure guidance downward to \u20b9450 crores from \u20b9600 crores, deferring \u20b9150 crores to FY27 during its recent conference call.",
            "Sentiment": "neutral",
            "PublishDate": 1769138671972,
            "Source": "stocks"
        },
        {
            "Title": "Alivus Life Sciences Raises EBITDA Margin Guidance",
            "Summary": "Alivus Life Sciences has revised its EBITDA margin guidance upward to 30-32% from the previous 28-30%, driven by operational efficiencies and new product launches announced during conference call.",
            "Sentiment": "positive",
            "PublishDate": 1769138645533,
            "Source": "co_actions_results"
        },
        {
            "Title": "Alivus Life Sciences Eyes High Single-Digit Growth",
            "Summary": "Alivus Life Sciences management projects high single-digit revenue growth for FY26 and beyond, driven by expansion in non-GPL segments and CDMO business ramp-up during recent conference call.",
            "Sentiment": "positive",
            "PublishDate": 1769138621172,
            "Source": "stocks"
        },
        {
            "Title": "Alivus Life Sciences Q3 Net Profit Rises to \u20b91.50B",
            "Summary": "Alivus Life Sciences reported net profit of \u20b91.50 billion in Q3, marking a 7.14% increase from \u20b91.40 billion in the same quarter of the previous year, demonstrating steady growth momentum.",
            "Sentiment": "positive",
            "PublishDate": 1769070467382,
            "Source": "co_actions_results"
        },
        {
            "Title": "Alivus Life Sciences Allots 55,000 ESOP Shares",
            "Summary": "Alivus Life Sciences Limited approved allotment of 55,000 equity shares under Employee Stock Option Scheme 2021, increasing paid-up share capital to \u20b924.55 crores on January 21, 2026.",
            "Sentiment": "positive",
            "PublishDate": 1769005676610,
            "Source": "co_actions_results"
        },
        {
            "Title": "Alivus Life Sciences Q3FY26 Earnings Call Jan 22",
            "Summary": "Alivus Life Sciences has scheduled its Q3 FY2025-26 earnings call for January 22, 2026, from 6:00 PM to 7:00 PM IST. The pharmaceutical company will discuss its third quarter financial performance with investors and analysts.",
            "Sentiment": "neutral",
            "PublishDate": 1768467564759,
            "Source": "co_actions_results"
        },
        {
            "Title": "Alivus Life Sciences Reports 16% Revenue Growth to INR 588 Crores in Q2 FY26",
            "Summary": "Alivus Life Sciences reported revenue of INR 588 crores for the quarter ended September 30, 2025, marking a 16% year-on-year growth. The company's non-GPL business drove performance with 39.7% growth, supported by successful new product launches. EBITDA margin expanded to 33%, up 480 basis points year-on-year, while gross margin reached 57.7%. PAT stood at INR 130 crores with a 22.1% margin. The GPL segment declined due to customer inventory rationalization but is expected to recover in the second half. For H1 FY26, revenue reached INR 1,190 crores with 8.6% growth. The company maintains its guidance of high single-digit revenue growth for FY26 and expects margins around 30% despite absence of PLI benefits. Alivus has 586 DMF and CEP filings globally and remains debt-free with INR 653 crores in cash and equivalents. Capacity expansion projects at Solapur, Ankleshwar and Dahej are progressing as planned.",
            "Sentiment": "positive",
            "PublishDate": 1763014919383,
            "Source": "earnings"
        },
        {
            "Title": "Alivus Life Sciences Plans Aggressive Growth in Specialty Formulations and Oncology",
            "Summary": "Alivus Life Sciences is targeting aggressive growth in specialty formulations and oncology segments with new U.S. and EU market approvals. The company is expanding its R&D pipeline and implementing backward integration strategies to strengthen margins. Alivus plans to launch more than 10 products in regulated markets while enhancing its contract development and manufacturing capabilities for global pharmaceutical clients.",
            "Sentiment": "positive",
            "PublishDate": 1762440312777,
            "Source": "stock"
        },
        {
            "Title": "Alivus Life Sciences Reports Strong Q2 Performance with EBITDA Growth",
            "Summary": "Alivus Life Sciences reported Q2 EBITDA of 1.8 billion rupees compared to 1.3 billion rupees in the same period last year. The company's EBITDA margin improved to 30.46% from 26.51% year-over-year, indicating enhanced operational efficiency and profitability.",
            "Sentiment": "positive",
            "PublishDate": 1762435831119,
            "Source": "earnings"
        },
        {
            "Title": "Alivus Life Sciences Reports 36% Jump in Q2 Net Profit to 1.3 Billion Rupees",
            "Summary": "Alivus Life Sciences reported net profit of 1.3 billion rupees in Q2, compared to 953 million rupees in the same period last year. The company's revenue increased to 5.9 billion rupees from 5.1 billion rupees year-over-year. This represents a 36% growth in net profit and a 16% increase in revenue compared to the previous year's corresponding quarter.",
            "Sentiment": "positive",
            "PublishDate": 1762435409982,
            "Source": "earnings"
        },
        {
            "Title": "Alivus Life Sciences Schedules Q2 FY2025-26 Earnings Call for November 7, 2025",
            "Summary": "Alivus Life Sciences Limited has announced an earnings call to discuss its Q2 FY2025-26 financial performance. The call is scheduled for Friday, November 7, 2025, from 8:30 a.m. to 9:30 a.m. IST. The company has provided multiple dial-in numbers for participants including universal numbers for India and international toll-free and toll numbers for various countries including Australia, Canada, China, Hong Kong, Italy, Japan, Singapore, South Korea, UK, and USA. Participants can pre-register online, and clarifications can be sought from Diwakar Pingle and Runjhun Jain at EY. The company operates under scrip code 543322 on BSE and scrip name ALIVUS on NSE.",
            "Sentiment": "neutral",
            "PublishDate": 1761840335391,
            "Source": "earnings"
        },
        {
            "Title": "Alivus Life Sciences Receives Rs 50 Lakh Environmental Penalty from Gujarat Pollution Control Board",
            "Summary": "Alivus Life Sciences Limited received a notice from the Gujarat Pollution Control Board imposing an interim Environment Damage Compensation of Rs 50 lakhs following a flash fire incident at unit No. 6 of its Ankleshwar Plant on September 30, 2025. The company must immediately deposit Rs 29 lakhs and submit a bank guarantee of Rs 10 lakhs for compliance assurance. The company stated there is no material impact on its financial position or operations due to the incident and penalty. The order is appealable and the company will assess exercising its right to appeal.",
            "Sentiment": "negative",
            "PublishDate": 1760934147616,
            "Source": "stock"
        },
        {
            "Title": "Alivus Life Sciences Reports 2.2% Revenue Growth in Q1 FY26 with Strong Margin Expansion",
            "Summary": "Alivus Life Sciences reported revenues of INR 602 crores for Q1 FY26, representing a 2.2% year-on-year growth. The company's non-GPL business grew 14.5% year-on-year, driven by successful new launches, while GPL business declined 22% due to inventory rationalization. Gross margins improved to 55.1%, up 400 basis points year-on-year, and EBITDA margins reached 30.1%, up 210 basis points. The company generated strong cash flows of INR 100 crores and maintains a net debt-free position with cash reserves of INR 660 crores. Both Dahej and Ankleshwar facilities received successful US FDA inspections with NAI classifications. The CDMO business remained subdued with validation batches for the fifth project commencing, expecting commercialization in H2. The company maintains guidance of high single-digit revenue growth for FY26 despite pricing pressures, with margins expected to remain in the 28-30% range. Capex guidance stands at INR 600 crores including carryover from previous year, with Solapur facility expected to begin operations in Q4.",
            "Sentiment": "positive",
            "PublishDate": 1754654866161,
            "Source": "earnings"
        },
        {
            "Title": "Alivus Life Sciences Reports Growth in Q1 Financial Performance",
            "Summary": "Alivus Life Sciences reported quarterly results showing revenue of 6.1 billion rupees compared to 5.9 billion rupees in the previous year. The company's EBITDA increased to 1.7 billion rupees from 1.6 billion rupees year-over-year, with EBITDA margin improving to 28.64% from 27.1%. Net profit rose to 1.2 billion rupees from 1.1 billion rupees in the same period last year.",
            "Sentiment": "positive",
            "PublishDate": 1754053979602,
            "Source": "earnings"
        },
        {
            "Title": "Alivus Life Sciences Receives USFDA No Action Indicated Classification for Gujarat API Facility",
            "Summary": "Alivus Life Sciences Limited received an Establishment Inspection Report with a No Action Indicated (NAI) classification from the USFDA for its API manufacturing facility located in Dahej, Gujarat. The classification follows a USFDA inspection conducted from May 26 to May 30, 2025. The NAI classification indicates that the facility met regulatory standards during the inspection. The company was formerly known as Glenmark Life Sciences Limited.",
            "Sentiment": "positive",
            "PublishDate": 1753527827079,
            "Source": "stock"
        },
        {
            "Title": "Alivus Life Sciences Schedules Q1 FY2025-26 Earnings Call for August 2, 2025",
            "Summary": "Alivus Life Sciences Limited has scheduled an earnings call to discuss its Q1 FY2025-26 financial performance on Saturday, August 2, 2025, from 8:30 AM to 9:30 AM IST. The company has provided multiple dial-in numbers for participants, including universal dial-in numbers for India and international toll-free and toll numbers for various countries including Australia, Canada, China, Hong Kong, Italy, Japan, Singapore, South Korea, UK, and USA. The company was formerly known as Glenmark Life Sciences Limited. Contact persons for clarifications are Diwakar Pingle and Runjhun Jain from EY.",
            "Sentiment": "neutral",
            "PublishDate": 1753366822870,
            "Source": "earnings"
        },
        {
            "Title": "Alivus Life Sciences Passes USFDA Inspection with Zero Observations",
            "Summary": "Alivus Life Sciences has successfully completed a USFDA GMP inspection at its Dahej API facility. The inspection resulted in zero Form 483 observations, indicating no significant issues were found during the regulatory review.",
            "Sentiment": "positive",
            "PublishDate": 1748584643000,
            "Source": "default"
        },
        {
            "Title": "Alivus Life Sciences Reports Q4 Results and Dividend Recommendation",
            "Summary": "Alivus Life Sciences announced its Q4 financial results and dividend recommendation. The company's Q4 EBITDA increased to 1.98 billion rupees from 1.41 billion rupees year-over-year, with EBITDA margin improving to 30.56% from 26.36%. Q4 net profit rose to 1.4 billion rupees from 980 million rupees year-over-year, remaining stable quarter-on-quarter. Revenue for Q4 grew to 6.5 billion rupees from 5.36 billion rupees year-over-year. The company has recommended a dividend of 5 rupees per equity share.",
            "Sentiment": "positive",
            "PublishDate": 1747321703000,
            "Source": "result"
        },
        {
            "Title": "Alivus Life Sciences to Consider Q4 Results on May 15",
            "Summary": "Alivus Life Sciences has announced that it will consider its fourth quarter (Q4) financial results on May 15. This indicates the company is preparing to release its latest quarterly earnings report, which will provide insights into its financial performance for the most recent fiscal period.",
            "Sentiment": "neutral",
            "PublishDate": 1746707932000,
            "Source": "default"
        },
        {
            "Title": "USFDA Issues EIR with VAI Status for Alivus Life Sciences' Ankleshwar Facility",
            "Summary": "Alivus Life Sciences has announced that the U.S. Food and Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) status for their facility in Ankleshwar. This indicates that while some objectionable conditions were found during the inspection, they do not warrant further regulatory action, and any proposed corrective actions will be evaluated during the next inspection.",
            "Sentiment": "positive",
            "PublishDate": 1743725113000,
            "Source": "corporate_governance"
        },
        {
            "Title": "Alivus Life Sciences to Acquire 9.21% Stake in Torrent Urja 19",
            "Summary": "Alivus Life Sciences has entered into an agreement with Torrent Urja 19 to acquire a 9.21% stake in the company. The acquisition cost is reported to be 156 million rupees.",
            "Sentiment": "neutral",
            "PublishDate": 1743639248000,
            "Source": "corporate_action"
        },
        {
            "Title": "Alivus Life Sciences Reports Q3 Revenue Growth",
            "Summary": "Alivus Life Sciences has reported a revenue of 6.4 billion rupees for the third quarter, compared to 5.73 billion rupees in the same period last year, indicating a year-over-year increase.",
            "Sentiment": "positive",
            "PublishDate": 1737622587000,
            "Source": "earnings"
        },
        {
            "Title": "Alivus Life Sciences Reports Q3 Net Profit Increase",
            "Summary": "Alivus Life Sciences has reported a net profit of 1.4 billion rupees for the third quarter, compared to 1.2 billion rupees in the same period last year, indicating a year-over-year increase in profitability.",
            "Sentiment": "positive",
            "PublishDate": 1737622451000,
            "Source": "earnings"
        },
        {
            "Title": "Glenmark Life Sciences Rebrands as Alivus Life Sciences",
            "Summary": "Glenmark Life Sciences has announced a rebranding initiative, changing its name to Alivus Life Sciences. This corporate action represents a significant change in the company's identity and potentially its strategic direction.",
            "Sentiment": "neutral",
            "PublishDate": 1737189333000,
            "Source": "corporate_action"
        },
        {
            "Title": "Glenmark Life Sciences to Change Name to Alivus Life Sciences Limited",
            "Summary": "Glenmark Life Sciences has announced a change in its company name. The new name, Alivus Life Sciences Limited, will take effect from January 20.",
            "Sentiment": "neutral",
            "PublishDate": 1736857929000,
            "Source": "corporate_action"
        },
        {
            "Title": "Glenmark Life Sciences to Change Name to Alivus Life Sciences",
            "Summary": "The Ministry of Corporate Affairs (MCA) has approved a name change for Glenmark Life Sciences. The company will be known as Alivus Life Sciences effective December 17, 2024.",
            "Sentiment": "neutral",
            "PublishDate": 1734482333000,
            "Source": "corporate_action"
        },
        {
            "Title": "Glenmark Life Sciences to Change Name to Alivus Life Sciences",
            "Summary": "The Ministry of Corporate Affairs (MCA) has approved a change in the company's name from Glenmark Life Sciences to Alivus Life Sciences. This change will take effect from December 17, 2024.",
            "Sentiment": "neutral",
            "PublishDate": 1734441857000,
            "Source": "corporate_action"
        },
        {
            "Title": "Kotak Upgrades Glenmark Life Sciences from Reduce to Buy",
            "Summary": "Kotak has issued a double upgrade for Glenmark Life Sciences, changing their recommendation from 'Reduce' to 'Buy'. This upgrade comes despite a temporary setback in Q2FY25 due to closure at the Ankleshwar facility. The company's curated API portfolio, rich pipeline, and recent CDMO client wins are expected to drive future growth.",
            "Sentiment": "positive",
            "PublishDate": 1730094282000,
            "Source": "normal_news"
        },
        {
            "Title": "Glenmark Life Sciences Reports Q2 EBITDA Decline",
            "Summary": "Glenmark Life Sciences announced its Q2 financial results. The company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) decreased to 1.3 billion rupees from 1.7 billion rupees year-over-year. The EBITDA margin also declined to 26.51% from 28.06% compared to the same period last year.",
            "Sentiment": "negative",
            "PublishDate": 1729776397000,
            "Source": "result"
        },
        {
            "Title": "Glenmark Life Sciences Reports Q2 Revenue Decline",
            "Summary": "Glenmark Life Sciences has reported a revenue of 5.1 billion rupees for the second quarter, down from 6 billion rupees in the same period last year, representing a year-over-year decrease.",
            "Sentiment": "negative",
            "PublishDate": 1729776389000,
            "Source": "result"
        },
        {
            "Title": "Glenmark Life Sciences Reports Q2 Net Profit Decline",
            "Summary": "Glenmark Life Sciences reported a net profit of 953 million rupees for the second quarter, showing a decrease from 1.2 billion rupees year-over-year and 1.1 billion rupees quarter-over-quarter.",
            "Sentiment": "negative",
            "PublishDate": 1729776380000,
            "Source": "result"
        },
        {
            "Title": "Glenmark Life Sciences: Rebranding to Alivus Life Sciences Post-Nirma Acquisition",
            "Summary": "<p><span class='neutral'>Glenmark Life Sciences</span> plans to <span class='neutral'>change its name</span> to <span class='neutral'>Alivus Life Sciences Limited</span> following <span class='positive'>acquisition</span> by <span class='neutral'>Nirma Limited</span>. The <b>board approved</b> the name change on <span class='neutral'>October 8, 2024</span>, subject to <span class='neutral'>shareholder and regulatory approvals</span>. The company's shares were trading <span class='positive'>up 0.46%</span> at <span class='neutral'>\u20b91,208.80</span> on the <span class='neutral'>NSE</span>.</p>",
            "Sentiment": "neutral",
            "PublishDate": 1728459601000,
            "Source": "corporate_action"
        }
    ]
}